UY37028A - Compuestos inhibidores de prostaglandina d sintasa ematopoyética (h-pgds - Google Patents
Compuestos inhibidores de prostaglandina d sintasa ematopoyética (h-pgdsInfo
- Publication number
- UY37028A UY37028A UY0001037028A UY37028A UY37028A UY 37028 A UY37028 A UY 37028A UY 0001037028 A UY0001037028 A UY 0001037028A UY 37028 A UY37028 A UY 37028A UY 37028 A UY37028 A UY 37028A
- Authority
- UY
- Uruguay
- Prior art keywords
- pgds
- ematopoyética
- prostaglandina
- sintasa
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Abstract
La presente invención se refiere a compuestos de Fórmula (XI):en donde R1a, R2a, R3a, R4a, R5a, R6a, y Aa son como se definen en la presente memoria, y a sales farmacéuticamente aceptables de los mismos. Los compuestos de la presente invención son inhibidores de prostaglandina D sintasa hematopoyética (H-PGDS) y pueden ser útiles en el tratamiento de la distrofia muscular de Duchenne. Por consiguiente, la invención se refiere adicionalmente a composiciones farmacéuticas que comprenden un compuesto de la invención. Además, la invención también se refiere a métodos para inhibir la actividad de H-PGDS y al tratamiento de trastornos asociados con ella usando un compuesto de la invención o una composición farmacéutica que comprende un compuesto de la invención.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562268630P | 2015-12-17 | 2015-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY37028A true UY37028A (es) | 2017-07-31 |
Family
ID=57589094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001037028A UY37028A (es) | 2015-12-17 | 2016-12-15 | Compuestos inhibidores de prostaglandina d sintasa ematopoyética (h-pgds |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210238162A1 (es) |
EP (1) | EP3390384B1 (es) |
JP (1) | JP2019502691A (es) |
KR (1) | KR20180095580A (es) |
CN (1) | CN108430992A (es) |
AR (1) | AR107044A1 (es) |
AU (1) | AU2016370779B2 (es) |
BR (1) | BR112018012469B1 (es) |
CA (1) | CA3008358A1 (es) |
RU (1) | RU2018126105A (es) |
TW (1) | TW201733988A (es) |
UY (1) | UY37028A (es) |
WO (1) | WO2017103851A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102603915B1 (ko) | 2015-07-02 | 2023-11-21 | 에프. 호프만-라 로슈 아게 | 이환형 락탐 및 이의 사용 방법 |
JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
CN109843886B (zh) | 2016-10-17 | 2022-04-19 | 豪夫迈·罗氏有限公司 | 二环吡啶酮内酰胺及其使用方法 |
US10889573B2 (en) | 2016-11-11 | 2021-01-12 | Bayer Animal Health Gmbh | Anthelmintic quinoline-3-carboxamide derivatives |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
CN110891935B (zh) | 2017-04-18 | 2023-12-01 | 泰普斯特医疗公司 | 双环化合物及其在癌症治疗中的用途 |
CA3066979A1 (en) | 2017-06-13 | 2018-12-20 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as h-pgds inhibitors |
JP7455294B2 (ja) | 2017-08-04 | 2024-03-26 | エランコ アニマル ヘルス ゲー・エム・ベー・ハー | 蠕虫による感染を治療するためのキノリン誘導体 |
CN111479814A (zh) * | 2017-12-13 | 2020-07-31 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为h-pgds抑制剂的稠合的吡啶 |
BR112020011901A2 (pt) | 2017-12-15 | 2020-11-24 | Bayer Animal Health Gmbh | processo para preparar derivados anti-helminticos de 4-amino-quinolina-3-carboxamida |
BR112020021042A2 (pt) * | 2018-04-17 | 2021-01-19 | Tempest Therapeutics, Inc. | Carboxamidas bicíclicas e métodos de uso das mesmas |
JP7398391B2 (ja) * | 2018-04-20 | 2023-12-14 | エフ. ホフマン-ラ ロシュ アーゲー | N-[4-オキソ-2,3-ジヒドロ-1,5-ベンズオキサゼピン-3-イル]-5,6-ジヒドロ-4H-ピロロ[1,2-b]ピラゾール-2-カルボキサミド誘導体及び例えば過敏性腸症候群(IBS)を処置するためのRIP1キナーゼ阻害剤としての関連化合物 |
MX2020011873A (es) | 2018-05-09 | 2021-01-20 | Bayer Animal Health Gmbh | Nuevos derivados de quinolina. |
WO2021204930A1 (en) | 2020-04-09 | 2021-10-14 | Bayer Animal Health Gmbh | Substituted condensed azines as anthelmintic compounds |
CN111549000B (zh) * | 2020-06-18 | 2022-07-29 | 中国医学科学院整形外科医院 | 一种过表达Hpgds的重组脂肪干细胞、制备方法及其应用 |
WO2021256569A1 (ja) | 2020-06-19 | 2021-12-23 | 佐藤製薬株式会社 | H-pgdsを阻害する縮環化合物 |
AU2022280865A1 (en) * | 2021-05-28 | 2023-11-09 | Merck Sharp & Dohme Llc | Synthesis of btk inhibitor and intermediates thereof |
EP4148052A1 (en) | 2021-09-09 | 2023-03-15 | Bayer Animal Health GmbH | New quinoline derivatives |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2122261T3 (es) | 1993-03-17 | 1998-12-16 | Minnesota Mining & Mfg | Formulacion de aerosol que contiene un adyuvante de dispersion derivado de un ester, una amida o un mercaptoester. |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
JP2003500480A (ja) * | 1999-06-02 | 2003-01-07 | エヌピーエス ファーマシューティカルズ インコーポレーテッド | 代謝型グルタミン酸受容体アンタゴニストおよび中枢神経系の疾病を治療するためのその使用 |
US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
WO2005094805A1 (ja) * | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | イミン誘導体及びアミド誘導体 |
TW200720255A (en) | 2005-07-13 | 2007-06-01 | Taiho Pharmaceutical Co Ltd | Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
JP2007051121A (ja) | 2005-07-22 | 2007-03-01 | Taiho Yakuhin Kogyo Kk | プロスタグランジンd合成酵素を阻害するピリミジン化合物 |
PE20070589A1 (es) | 2005-10-04 | 2007-06-22 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
WO2008075172A2 (en) | 2006-12-19 | 2008-06-26 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
CA2682629C (en) | 2007-03-30 | 2013-03-19 | Sanofi-Aventis | Pyrimidine hydrazide compounds as pgds inhibitors |
GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
EP2231666B1 (en) * | 2007-12-12 | 2015-07-29 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
TW201010997A (en) | 2008-06-18 | 2010-03-16 | Pfizer Ltd | Nicotinamide derivatives |
WO2009153721A1 (en) * | 2008-06-18 | 2009-12-23 | Pfizer Limited | Nicotinamide derivatives |
EP2350059B1 (en) | 2008-09-22 | 2016-03-23 | Cayman Chemical Company | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
SG173865A1 (en) | 2009-03-09 | 2011-09-29 | Taiho Pharmaceutical Co Ltd | Piperazine compound capable of inhibiting prostaglandin d synthase |
US20120196854A1 (en) | 2009-10-06 | 2012-08-02 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical composition comprising aromatic heterocyclic compound |
BR112012007635B1 (pt) | 2009-10-08 | 2019-07-09 | Sanofi | Compostos derivados de feniloxadiazol como inibidores de pgds, composição farmacêutica compreendendo os mesmos e seus processos de preparação |
EP2527340B1 (en) | 2010-01-22 | 2016-08-17 | Taiho Pharmaceutical Co., Ltd. | Piperazine compound having a pgds inhibitory effect |
EP2872493B1 (en) * | 2012-07-13 | 2018-11-14 | Indiana University Research and Technology Corporation | 5,6,7-trimethoxy 4-phenyl quinolin-2-one derivatives for treatment of spinal muscular atrophy |
-
2016
- 2016-12-15 CA CA3008358A patent/CA3008358A1/en not_active Abandoned
- 2016-12-15 WO PCT/IB2016/057676 patent/WO2017103851A1/en active Application Filing
- 2016-12-15 US US16/062,223 patent/US20210238162A1/en not_active Abandoned
- 2016-12-15 JP JP2018531378A patent/JP2019502691A/ja active Pending
- 2016-12-15 UY UY0001037028A patent/UY37028A/es unknown
- 2016-12-15 EP EP16815960.6A patent/EP3390384B1/en active Active
- 2016-12-15 KR KR1020187019904A patent/KR20180095580A/ko unknown
- 2016-12-15 TW TW105141512A patent/TW201733988A/zh unknown
- 2016-12-15 CN CN201680074158.0A patent/CN108430992A/zh active Pending
- 2016-12-15 BR BR112018012469-9A patent/BR112018012469B1/pt not_active IP Right Cessation
- 2016-12-15 AR ARP160103847A patent/AR107044A1/es unknown
- 2016-12-15 AU AU2016370779A patent/AU2016370779B2/en not_active Expired - Fee Related
- 2016-12-15 RU RU2018126105A patent/RU2018126105A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2018126105A (ru) | 2020-01-17 |
EP3390384A1 (en) | 2018-10-24 |
JP2019502691A (ja) | 2019-01-31 |
CA3008358A1 (en) | 2017-06-22 |
BR112018012469B1 (pt) | 2020-11-24 |
BR112018012469A2 (pt) | 2018-12-18 |
US20210238162A1 (en) | 2021-08-05 |
CN108430992A (zh) | 2018-08-21 |
TW201733988A (zh) | 2017-10-01 |
AU2016370779A1 (en) | 2018-06-14 |
AU2016370779B2 (en) | 2019-07-25 |
EP3390384B1 (en) | 2021-09-15 |
KR20180095580A (ko) | 2018-08-27 |
WO2017103851A1 (en) | 2017-06-22 |
AR107044A1 (es) | 2018-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY37028A (es) | Compuestos inhibidores de prostaglandina d sintasa ematopoyética (h-pgds | |
DOP2019000030A (es) | Inhibidores de cdk2/4/6 | |
CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
CR20150045A (es) | Inhibidores de hepatitis c | |
ECSP18040250A (es) | Composiciones y métodos para inhibir la actividad arginasa | |
DOP2018000273A (es) | Compuestos químicos | |
CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
UY35242A (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
CR20140361A (es) | Inhibidores de pde9 con estructura básica de imidazotriazinona | |
UY35663A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
PE20151423A1 (es) | Derivados tetrahidropiranilo inhibidores del hcv | |
DOP2014000204A (es) | Compuestos de heterociclilo como inhibidores de mek | |
MX2015012850A (es) | Inhibidores de la arginina metiltransferasa y usos de los mismos. | |
ECSP12012103A (es) | Inhibidores de virus flaviviridae. | |
ECSP17013903A (es) | Protein kinase c inhibitors and methods of their use | |
CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
DOP2019000087A (es) | Compuestos químicos | |
CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
PH12014501283A1 (en) | 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication | |
GT201400261A (es) | Solicitud pct face nacional novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa | |
CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
NI201600014A (es) | Compuestos y composiciones como inhibidores de la mek. | |
PH12016501461A1 (en) | 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors | |
CO2019010559A2 (es) | Composiciones y compuestos terapéuticos y métodos para utilizarlos |